• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy.
【24h】

T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy.

机译：慢病毒载体在过继细胞治疗中的T细胞受体基因转移。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Adoptive cell therapy can be envisioned as a promising strategy for tumour immunotherapy. However, existing protocols of adoptive cell therapy still require optimisation as many factors, such as specificity, avidity, level of differentiation and amount of transferred T lymphocytes, can influence their immunocompetence and in vivo functionality. In particular, the need to reduce the in vitro expansion phase and to obtain large numbers of tumour-reactive T cells, as a favourable condition for cancer regression, make TCR gene transfer a potentially ideal tool to overcome the limits of adoptive cell therapy strategies. Here, the authors review the state-of-the-art and recent advances in TCR transfer with particular emphasis on lentiviral vector systems. Initial data from preclinical models and recent clinical trials encourage optimisation of a safe, simplified and stable transfer system. In this regard, HIV-based vectors are emerging as good alternative candidates over the most widely used oncoretroviral vectors due to their peculiar molecular features that fit the ideal conditions for donor T cell in vitro manipulation.
机译：可以将过继细胞疗法设想为肿瘤免疫疗法的有前途的策略。然而，现有的过继细胞疗法方案仍需要优化，因为许多因素（例如特异性，亲和力，分化水平和转移的T淋巴细胞数量）可能会影响其免疫能力和体内功能。尤其是，减少体外扩增阶段并获得大量肿瘤反应性T细胞作为癌症消退的有利条件，使TCR基因转移成为克服过继细胞治疗策略局限性的潜在理想工具。在这里，作者回顾了TCR转移的最新技术和最新进展，特别着重于慢病毒载体系统。临床前模型的初步数据和最近的临床试验都鼓励优化安全，简化和稳定的转运系统。在这方面，基于HIV的载体由于其独特的分子特征适合于供体T细胞体外操作的理想条件，因此已经成为最广泛使用的核转病毒载体的替代候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号